TRVNTrevena, Inc.

About Trevena, Inc. (TRVN)

Trevena, Inc. (TRVN) is a Biotechnology company headquartered in Chesterbrook, PA, United States whose shares trade over-the-counter on the Pink tier.

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

TRVN key facts

Ticker symbol

TRVN

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Chesterbrook, PA, United States

Country of incorporation

US

Estimated market cap

$1.04M (as of Apr 10, 2025)

Shares outstanding

863,788

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Jan 31, 2025)

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with T